Methods and compositions for the sustained release of chromium
View Patent ↗Provided herein are compositions for the administration of chromium that include at least two components: a hydrophilic chromium complex and a lipophilic chromium complex, and methods of using the same. Also provided are compositions for the administration of chromium that include a first “fast-acting” chromium complex and a second “slow-acting” chromium complex, wherein the first chromium complex is absorbed more quickly than the slow-acting chromium complex, and methods of using the same. Also provided herein are methods for treating, preventing, and improving conditions associated with cardiometabolic syndrome, by identifying a subject in need of treatment, prevention, or improvement of a condition associated with cardiometabolic syndrome, and providing a therapeutically effective amount of a composition comprising a fast-acting chromium complex and a slow-acting chromium complex, to the individual.
1. A method for reducing the risk of developing cardiometabolic syndrome in a subject, comprising:
co-administering to said subject a therapeutically effective amount of a synergistic ratio of chromium provided in the form of a hydrophilic chromium complex to chromium provided in the form of a lipophilic chromium complex; wherein the ratio of chromium provided in the form of a hydrophilic chromium complex to chromium provided in the form of a lipophilic chromium complex is between about 1:10 and about 10:1.
2. The method of claim 1 , wherein said hydrophilic chromium complex is selected from the group consisting of chromium histidinate, chromium acetate, chromium chloride, and chromium nicotinate.
3. The method of claim 1 , wherein said hydrophilic chromium complex and said lipophilic chromium complex are administered at substantially the same time.
4. The method of claim 1 , wherein said hydrophilic chromium complex and said lipophilic chromium complex are administered sequentially in either order.
5. The method of claim 1 , wherein said hydrophilic chromium complex is chromium histidinate.
6. The method of claim 1 , wherein said hydrophilic chromium complex is chromium acetate.
7. The method of claim 1 , wherein said hydrophilic chromium complex is chromium chloride.
8. The method of claim 1 , wherein said hydrophilic chromium complex is chromium nicotinate.
9. The method of claim 1 , wherein said lipophilic chromium complex is chromium picolinate.
10. The method of claim 1 , wherein the ratio of chromium provided in the form of a hydrophilic chromium complex to chromium provided in the form of a lipophilic chromium complex is between about 1:8 and about 8:1.
11. The method of claim 1 , wherein the ratio of chromium provided in the form of a hydrophilic chromium complex to chromium provided in the form of a lipophilic chromium complex is between about 1:4 and about 4:1.
12. The method of claim 1 , wherein the ratio of chromium provided in the form of a hydrophilic chromium complex to chromium provided in the form of a lipophilic chromium complex is between about 1:2 and about 2:1.
13. The method of claim 1 , wherein the subject is a mammal.
14. The method of claim 13 , wherein the mammal is a human.
15. The method of claim 1 , wherein the chromium is administered concurrently with a therapeutically effective amount of a cardiovascular compound.
16. The method of claim 15 , wherein the cardiovascular compound is selected from the group consisting of an angiotensin converting enzyme inhibitor, an angiotensin II receptor antagonist, a calcium channel blocker, an anti-thrombotic agent, a β-adrenergic receptor antagonist, a vasodilator, a diuretic, an α-adrenergic receptor antagonist, an antioxidant, and combinations thereof.
17. A method for treating cardiometabolic syndrome in a subject in need thereof, comprising:
identifying a subject having at least one risk factor for cardiometabolic syndrome; and
administering to said subject a therapeutically effective amount of a synergistic ratio of chromium provided in the form of a hydrophilic chromium complex to chromium provided in the form of a lipophilic chromium complex; wherein the ratio of chromium provided in the form of a hydrophilic chromium complex to chromium provided in the form of a lipophilic chromium complex is between about 1:10 and about 10:1.
18. The method of claim 17 , wherein said hydrophilic chromium complex is selected from the group consisting of chromium histidinate, chromium acetate, chromium chloride, and chromium nicotinate.
19. The method of claim 17 , wherein said lipophilic chromium complex is chromium picolinate.